Prelude Capital Management, LLC Bio N Tech Se Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $12,325 - $18,624	-100 Reduced 2.76%	3,525 $526,000
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $378 - $695	-3 Reduced 0.08%	3,625 $618,000
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $866 - $1,450	-4 Reduced 0.11%	3,628 $935,000
Q3 2021 Nov 15, 2021	SELL	$205.93 - $447.23 $230,229 - $500,003	-1,118 Reduced 23.54%	3,632 $991,000
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $158,648 - $338,086	1,400 Added 41.79%	4,750 $1.06 Million
Q1 2021 May 17, 2021	SELL	$85.73 - $119.5 $68,584 - $95,600	-800 Reduced 19.28%	3,350 $366,000
Q3 2020 Nov 16, 2020	BUY	$57.81 - $104.17 $133,945 - $241,361	2,317 Added 126.4%	4,150 $287,000
Q2 2020 Aug 14, 2020	BUY	$38.58 - $66.74 $70,717 - $122,334	1,833 New	1,833 $122,000

328

40.6M

845K

1.23M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.